Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.53 |
| ▸ | APOB | P04114 | 9/20 | 0.53 |
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | UGCG | Q16739 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788348 | 0.95 | MTTP (0.51) | MTTPAPOBSMOSMN1; SMN2KDM4E | |
| SCHEMBL6488352 | 0.89 | SMO (0.45) | MTTPAPOBSMOADORA3 | |
| SCHEMBL6793643 | 0.88 | MTTP (0.51) | MTTPAPOBSMOKDM4EUGCG | |
| SCHEMBL6792606 | 0.87 | MTTP (0.49) | MTTPAPOBSMOUGCG | |
| SCHEMBL6799624 | 0.87 | PTGS1 (0.50) | MTTPAPOBSMOSMN1; SMN2PTGS1 | |
| SCHEMBL6793400 | 0.86 | POLB (0.58) | SMN1; SMN2KDM4ELMNA | |
| SCHEMBL6792654 | 0.85 | MTTP (0.49) | MTTPAPOBSMOSMN1; SMN2KDM4E | |
| SCHEMBL6800458 | 0.85 | MTTP (0.49) | MTTPAPOBSMO | |
| SCHEMBL6787479 | 0.85 | AOC3 (0.52) | MTTPAPOBLMNA | |
| SCHEMBL6488561 | 0.84 | SMO (0.43) | MTTPAPOBSMOADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885SMO 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.